• Applied Workflows with Bromodomain Inhibitor, (+)-JQ1

  2026-06-19

  Bromodomain Inhibitor, (+)-JQ1 empowers researchers with precise BET bromodomain inhibition, enabling advanced apoptosis and inflammation studies as well as non-hormonal male contraception models. This article details optimized experimental workflows, troubleshooting strategies, and highlights key innovations from recent translational research.

• A-769662: Mechanistic Insights into AMPK Activation & Metabo

  2026-06-19

  A-769662 is a potent, reversible AMPK activator used in metabolic research. It inhibits anabolic pathways and modulates autophagy via allosteric AMPK activation. Its dual action and unique specificity recommend it for precise energy metabolism studies.

• PNU 74654: Wnt Signaling Pathway Inhibitor for Research Use

  2026-06-18

  PNU 74654 is a validated Wnt signaling pathway inhibitor with high specificity, optimized for research in cell proliferation and differentiation. It offers robust performance in Wnt/β-catenin pathway modulation, supporting cancer and stem cell studies.

• Phosphatase Inhibitor Cocktail 2: Optimizing Phosphoprotein

  2026-06-18

  Harnessing the broad-spectrum efficacy of Phosphatase Inhibitor Cocktail 2 ensures reliable preservation of protein phosphorylation in cellular extracts, powering robust signal transduction and neurodegeneration research. This guide demystifies experimental setup, highlights advanced applications, and delivers actionable troubleshooting strategies for reproducible, high-impact results.

• Nigericin Sodium Salt: Translational Leverage for Ion Transp

  2026-06-17

  This thought-leadership article dissects the strategic value of Nigericin sodium salt as a potassium ionophore, bridging mechanistic insight with translational guidance for researchers. Emphasizing its role in ion transport across biological membranes and its impact on cell viability, pH regulation, and toxicology workflows, the article contextualizes Nigericin’s unique selectivity for lead (Pb2+) ions and its implications for advanced assay development. Integrated evidence from recent in vitro studies and competitive analysis highlight why APExBIO’s Nigericin sodium salt stands as a pivotal tool for next-generation translational research.

• Dose Compliance of Estramustine and Degarelix in High-Risk P

  2026-06-17

  This prospective study reveals that maintaining estramustine phosphate dosing during neoadjuvant chemohormonal therapy combined with degarelix acetate significantly predicts better biochemical recurrence-free survival in very high-risk prostate cancer patients undergoing robot-assisted radical prostatectomy. The findings provide actionable insights for optimizing preoperative therapy regimens and highlight the importance of dose adherence and adverse event management.

• Reliable Pulmonary Fibrosis Assays with Salvianolic acid B (

  2026-06-16

  This article explores real laboratory challenges in pulmonary fibrosis and extracellular matrix research, emphasizing how Salvianolic acid B (SKU N1806) from APExBIO delivers reproducible, high-purity solutions for collagen synthesis inhibition and LH2 targeting. Scenario-driven Q&A blocks provide evidence-backed guidance for assay optimization and product selection.

• Tamoxifen as a Selective Estrogen Receptor Modulator: Eviden

  2026-06-16

  Tamoxifen is a selective estrogen receptor modulator with established roles in breast cancer research, CreER-mediated gene knockout, and kinase inhibition. Its multifaceted mechanism enables both estrogen antagonism in breast tissue and unique activation pathways in other cell types. APExBIO supplies high-purity Tamoxifen (B5965) optimized for research applications.

• Formononetin Prevents Oxaliplatin Neurotoxicity via Nrf2/HO-

  2026-06-15

  The reference study identifies formononetin as a neuroprotectant that shields dorsal root ganglion neurons from oxaliplatin-induced peripheral neurotoxicity by activating the Nrf2/HO-1 antioxidant pathway, without diminishing chemotherapy efficacy. These findings address the longstanding challenge of preventing chemotherapy-induced neuropathy while preserving anticancer action.

• 6-Thioguanine Inhibits EV71 via BIRC3-Mediated Autophagy Sup

  2026-06-15

  You et al. demonstrate that 6-thioguanine (6-TG) potently inhibits enterovirus 71 (EV71) replication by attenuating BIRC3-mediated autophagy in human cells. This mechanistic insight not only advances our understanding of 6-TG’s antiviral action but also suggests research pathways for therapeutic intervention in EV71-associated hand, foot, and mouth disease.

• Virus-Mimicking Nanoparticles Enable Extrahepatic mRNA Deliv

  2026-06-14

  This study introduces a modular, self-assembling enveloped virus-mimicking particle (EVMP) platform that achieves robust, targeted delivery of mRNA to extrahepatic organs, notably the lungs and spleen. The work addresses the limitations of hepatic tropism in conventional lipid nanoparticle systems, offering a programmable and low-immunogenicity solution for expanding mRNA therapeutics beyond the liver.

• Merimepodib (VX-497): Advanced Workflows in Antiviral & Immu

  2026-06-13

  Merimepodib (VX-497) is uniquely positioned as a noncompetitive, orally bioavailable IMPDH inhibitor for dissecting nucleotide biosynthesis in cancer, immunosuppressive, and antiviral research. This article delivers a protocol-driven guide to leveraging Merimepodib for robust experimental outcomes, highlighting workflow design, troubleshooting, and recent breakthroughs from PEDV and broader virology literature.

• Unlocking Proteomics: Pronase E Protease Mixture in TNBC Res

  2026-06-12

  Pronase E (Activity ≥ 7000 U/g) enables broad-spectrum, high-yield protein digestion crucial for proteomics and mechanistic oncology workflows. This article bridges reference breakthroughs in ferroptosis and practical laboratory enhancements, with actionable troubleshooting and stepwise guidance to maximize reproducibility and data clarity.

• JZL184: Monoacylglycerol Lipase Inhibitor for Neuropharmacol

  2026-06-12

  JZL184, a highly selective monoacylglycerol lipase inhibitor from APExBIO, unlocks precise modulation of endocannabinoid signaling for advanced neuropharmacological and pain research. This guide translates recent mechanistic breakthroughs into optimized workflows and troubleshooting strategies, ensuring reproducibility and clarity for both established and emerging applications.

• ECL Chemiluminescent Substrate Detection Kit: Advanced HRP C

  2026-06-11

  The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) by APExBIO transforms immunoblotting workflows with ultra-sensitive HRP chemiluminescence, enabling reliable detection of low-abundance proteins. Its robust signal stability and low background empower researchers to resolve challenging protein targets in translational disease models.

451 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page